Viewing Study NCT03471351


Ignite Creation Date: 2025-12-24 @ 11:54 PM
Ignite Modification Date: 2025-12-25 @ 9:50 PM
Study NCT ID: NCT03471351
Status: TERMINATED
Last Update Posted: 2019-12-27
First Post: 2018-02-15
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Sponsor: Rhizen Pharmaceuticals SA
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module